Stabilized antihistamine syrup
View Patent ↗An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.
1. A syrup formulation containing an antihistaminic amount of azatadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.
2. The syrup of claim 1 , wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.
3. The syrup of claim 1 , wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.
4. The syrup of claim 1 , in which the aminopolycarboxylic acid comprises about 0.1 to about 1 mg/mL.
5. The syrup of claim 1 , in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.
6. The syrup of claim 1 , further containing a therapeutically effective amount of a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more thereof.
7. The syrup of claim 1 , further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.
8. The syrup of claim 1 , further containing the decongestant pseudoephedrine.
9. An antihistaminic syrup formulation containing azatadine and about 0.05 to about 5 mg/mL of a sodium salt of ethylenediaminetetraacetic acid.
10. The syrup of claim 9 , which the salt of ethylenediaminetetraacetic acid comprises about 0.1 to about 1 mg/mL.
11. The syrup of claim 9 , in which the salt of ethylenediaminetetraacetic acid comprises about 0.25 to about 0.5 mg/mL.
12. The syrup of claim 9 , further containing an analgesic.
13. The syrup of claim 9 , further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.
14. An antihistaminic syrup formulation containing azatadine and about 0.05 to about 5 mg/mL of the disodium salt of ethylenediaminetetraacetic acid.
15. The syrup of claim 14 , in which the disodium salt of ethylenediaminetetraacetic acid comprises about 0.1 to about 1 mg/mL.
16. The syrup of claim 14 , in which the disodium salt of ethylenediaminetetrascetic acid comprises about 0.25 to about 0.5 mg/mL.
17. The syrup of claim 14 , further containing an analgesic.
18. The syrup of claim 14 , further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.
19. The syrup of claim 18 , further containing an analgesic.